A Phase I/II Study of HE3235 in Patients With Prostate Cancer
NCT00716794
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
HE3235
Sponsor
Harbor Therapeutics